EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations

Xiao-Lian Liu, Zhou Run-Hua, Jing-Xuan Pan, Zhi-Jie Li, Le Yu, Yi-Lei Li

Pigment Cell & Melanoma Research · 2024-05 · 37 (3) · 411-425

DOI: 10.1111/pcmr.13161 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 27.02.2024. Verfasst von Xiao-Lian Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma, Mutation. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults. Although primary UM can be effectively controlled, a significant proportion of cases (40% or more) eventually develop distant metastases, commonly in the liver. Metastatic UM remains a lethal disease with limited treatment options. The initiation of UM is typically attributed to activating mutations in GNAQ or GNA11 . The elucidation of the downstream pathways such as PKC/MAPK, PI3K/AKT/mTOR, and Hippo‐YAP have provided potential therapeutic targets. Concurrent mutations in BRCA1 associated protein 1 ( BAP1 ) or splicing factor 3b subunit 1 ( SF3B1 ) are considered crucial for the acquisition of malignant potential. Furthermore, in preclinical studies, actionable targets associated with BAP1 loss or oncogenic mutant SF3B1 have been identified, offering promising avenues for UM treatment. This review aims to summarize the emerging targeted and epigenetic therapeutic strategies for metastatic UM carrying specific driver mutations and the potential of combining these approaches with immunotherapy, with particular focus on those in upcoming or ongoing clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uveal NeoplasmsMelanomaMutationHumansMolecular Targeted TherapyNeoplasm MetastasisAnimalsImmunotherapyUveal Melanoma

Stichwörter der Autor:innen

clinical trialsdriver mutationsepigenetic therapyimmunotherapytargeted therapyuveal melanoma

Autor:innen und Institutionen

  • Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
  • Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, X. L., Run-Hua, Z., Pan, J. X., Li, Z. J., Yu, L., & Li, Y. L. (2024). Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations. Pigment Cell & Melanoma Research, 37(3), 411-425. https://doi.org/10.1111/pcmr.13161

Vancouver

Liu XL, Run-Hua Z, Pan JX, Li ZJ, Yu L, Li YL. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations. Pigment Cell & Melanoma Research. 2024;37(3):411-425. doi:10.1111/pcmr.13161

BibTeX
@article{Liu2024,
  author = {Liu, Xiao-Lian and Run-Hua, Zhou and Pan, Jing-Xuan and Li, Zhi-Jie and Yu, Le and Li, Yi-Lei},
  title = {Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations},
  journal = {Pigment Cell & Melanoma Research},
  year = {2024},
  volume = {37},
  number = {3},
  pages = {411--425},
  doi = {10.1111/pcmr.13161}
}
Kostenlos starten →